A significant analyst price target hike for Quantum Computing Inc. (QUBT) fuels a massive rally in the leveraged ETF.
Regulators expedite review for ALTO-101, a novel treatment for cognitive impairment in schizophrenia, a condition with no currently approved therapies.
Shares surge over 76% as the company secures Nevada Tech Hub funding and a key U.S. patent for its charging technology.
Health insurer's stock rallies as it maintains financial targets despite recent Medicare Star Ratings challenges.
GM, Ford, and Stellantis shares climb on news of potential tariff exemptions for U.S. vehicles, signaling a policy shift.
Singapore-based security firm Concorde International Group sees massive trading volume without any apparent news catalyst, prompting investor caution.
Government award will advance the company's non-vaccine influenza therapeutic, CD388, and onshore its manufacturing ahead of a potential pandemic.
Regulators expedite review for ALTO-101, targeting a key aspect of schizophrenia with no currently approved treatments.